CRISPR-CAS9 in Cancer Immunotherapy
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell and Gene Therapy".
Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 2585
Special Issue Editor
Special Issue Information
Dear Colleagues,
CRISPR-CAS9 was awarded the 2020 Nobel Prize in chemistry, after its inception in 2011–2012, because of its revolutionary impact in the field of life sciences. With its adapted ability to precisely edit genomes in mammalian cells, including cancer and T cells, it has been widely used in studies of cancer immunotherapies, including immune checkpoint blockers (ICBs), chimeric antigen receptor T cells (CAR-T), and T-cell receptor T cells (TCR-T). For example, systemic screening of cancer cells with sgRNA libraries identified vulnerable genes in different tumor genotypes and unveiled genetic perturbations that drive therapeutic resistance to ICBs (e.g., loss of IFN-g signaling and antigen presentation machinery genes); conversely, knockout of the RNA-editing enzyme ADAR1 in tumor cells could overcome ICB resistance. With respect to its applications in T cells, deletion of negative regulators of T cell activation, immune checkpoints (i.e., PD-1 and CTLA-4), and key regulators of T cell exhaustion enhanced the anti-tumor function of CAR-T and TCR-T cells; additionally, by removing the TCRa and b chains in allogeneic T cells that cause graft vs. host disease and allorejection, this could improve the safety and accessibility of CAR-T cells. Given these exciting developments, in this Special Issue, we cordially invite cutting-edge research papers, insightful perspectives, and constructive reviews on CRISPR-CAS9 in cancer immunotherapy.
Dr. Lewis Zhichang Shi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
